中国肿瘤生物治疗杂志2017，Vol.24Issue(8)：870-874,5.DOI:10.3872/j.issn.1007-385x.2017.08.009
替莫唑胺联合舒尼替尼治疗转移性黏膜黑色素瘤的疗效及安全性
Efficacy and safety analysis of temozolomide combined with sunitinib in treatment of metastatic mucosal melanoma
摘要
Abstract
Objective:To investigate the application value oftemozolomide (TMZ) combined with sunitinib (SUN) in the treatment of metastatic mucosal melanoma.Methods:This research retrospectively analyzed the data of patients with metastatic mucosal melanoma that treated with TMZ combined with SUN in Peking University Cancer Hospital from August,2008 to December,2016.Patients showed no BRAF~RAS mutation.The combination regimen of SUN (37.5 mg,dl-28) and TMZ (200 mg/m2,d1-5) was continued in a 28-days cycle until disease progression or toxicity intolerance.The primary observation indices were objective response rate (ORR),progression-free survival (PFS),overall survival (OS) and toxic side effect rate.Results:Among the included 27 patients,primary intestinal lesion occurred in 4 patients,genitourinary lesion occurred in 9 patient,nasal lesions in 5 patient,oral lesions in 7 patients and esophagal lesion in 2 patients;19 patients had been previously treated with anti-tumor treatment.Median treatment cycle was 3.0 of TMZ combined with SUN treatment.ORR was 19.2％,disease control rate was 81.5％,median PFS and OS were (3.0±0.7) months and (7.1 ±0.9) months,respectively.KIT mutation was detected in 4 patients,and the use of KIT inhibitor might be beneficial to those patients.The combination therapy was well tolerated,and only 2 patients required a dose reduction of SUN to 25 mg due to thrombocytopenia (grade IV).Grade Ⅲ-Ⅳ toxicities mainly included thrombocytopenia (19.2％),leucopenia (19.2％),and hepatic injury (3.9％).No treatment related death occurred.Conclusion:For metastatic mucosal melanoma,TMZ+SUN might be an effective and safe approach.关键词
黏膜黑色素瘤/替莫唑胺/舒尼替尼Key words
mucosal melanoma/temozolomide/sunitinib分类
医药卫生引用本文复制引用
唐碧霞,王轩,白雪,周莉,郭军,斯璐,迟志宏,盛锡楠,崔传亮,鄢谢桥,李思明,毛丽丽,连斌..替莫唑胺联合舒尼替尼治疗转移性黏膜黑色素瘤的疗效及安全性[J].中国肿瘤生物治疗杂志,2017,24(8):870-874,5.基金项目
国家重点基础研究发展计划(973计划)资助项目(No.2013CB911004).Project supported by the National Program on Key Basic Research Project of China (973 Project) (No.2013CB911004) （973计划）
